ELISA Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1)

CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1

Specificity

This assay has high sensitivity and excellent specificity for detection of Programmed Cell Death Protein 1 Ligand 1 (PDL1).
No significant cross-reactivity or interference between Programmed Cell Death Protein 1 Ligand 1 (PDL1) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Programmed Cell Death Protein 1 Ligand 1 (PDL1) and the recovery rates were calculated by comparing the measured value to the expected amount of Programmed Cell Death Protein 1 Ligand 1 (PDL1) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 88-97 92
EDTA plasma(n=5) 81-95 90
heparin plasma(n=5) 95-105 101

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Programmed Cell Death Protein 1 Ligand 1 (PDL1) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Programmed Cell Death Protein 1 Ligand 1 (PDL1) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Programmed Cell Death Protein 1 Ligand 1 (PDL1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 82-104% 96-104% 81-90% 90-104%
EDTA plasma(n=5) 80-97% 84-98% 82-91% 78-93%
heparin plasma(n=5) 80-89% 84-102% 97-104% 89-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Chinese Journal of Cancer Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications NCBI: PMC3937742
Leukemia.? High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Pubmed:24732592
Diabetes?Metab Res Rev. PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile Pubmed:24816853
Lancet Haematol Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study PubMed: 26686046
Eur J Cancer.  High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Pubmed:27039170
Journal of Cancer Research and Clinical Oncology Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer article:10.1007
Journal of Hematology & Oncology PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma pubmed:27737703
Lung Cancer. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. pubmed:28212990
Oncotarget Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predictssurvival in advanced biliary tract cancer patients treated with palliative chemotherapy. pubmed:27780932
Oncotarget High post-treatment serum levels of soluble programmed cell death ligand 1 predict earlyrelapse and poor prognosis in extranodal NK/T cell lymphoma patients. pubmed:27105512
Oncotarget.  Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma pubmed:27566569
Cancer Immunol Immunother. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. pubmed:28349165
Leukemia Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients leu2016385a
Medicine Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. pubmed:28207525
Allergology International  Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients pubmed:27617656
Medicine Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy PMC5319514
American Journal of Respiratory and Critical Care Medicine Soluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM) Pdf:10.1164
Clinical Lung Cancer Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer Pubmed:29859759
Journal of Rheumatology Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis Pubmed:29419471
Translational Oncology High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma Pubmed:29698935
Immunology Letters Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals Pubmed: 30236481
Journal of Cancer Research and Clinical Oncology Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma Pubmed: 30267213
Annals of Surgical Oncology Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between … Pubmed: 30565045
American Journal of Reproductive Immunology Identification of programmed cell death 1 and its ligand in the testicular tissue of mice Pubmed: 30578744
PLoS One Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated … Pubmed: 30807610
Endocrine Connections Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer Pubmed: 31252406
Scientific Reports Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer Pubmed: 31366979
Critical Reviews in Oncology / Hematology The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer Pubmed: 31675543
PLoS One Clinical implications of APOBEC3A and 3B expression in patients with breast cancer Pubmed: 32176735
Cancers Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study Pubmed: 32085544
Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma Pubmed: 32054467
LIVER INTERNATIONAL The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer Pubmed: 32780918
CANCER IMMUNOLOGY IMMUNOTHERAPY Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients Pubmed: 32577816
Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure Pubmed: 32443313
Cancer Immunol Immunother The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte 33688997
Acta Biochim Biophys Sin Prognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management 34180502
EMBO J Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology 34825707
Mol Pharm A Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors 34910492
Mol Hum Reprod Macrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis Pubmed:35404426
Journal of Nanobiotechnology Microbial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape Pubmed:35705974
Medicina Assessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A … Pubmed:35208526
Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
RPA788Mu01 Recombinant Programmed Cell Death Protein 1 Ligand 1 (PDL1) Positive Control; Immunogen; SDS-PAGE; WB.
RPA788Mu02 Recombinant Programmed Cell Death Protein 1 Ligand 1 (PDL1) Positive Control; Immunogen; SDS-PAGE; WB.
PAA788Mu01 Polyclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1) WB; IHC; ICC; IP.
PAA788Mu02 Polyclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1) WB; IHC; ICC; IP.
SEA788Mu ELISA Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA788Mu Multiplex Assay Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.